Gain Therapeutics, Inc. GANX
We take great care to ensure that the data presented and summarized in this overview for Gain Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GANX
View all-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.13 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.09 Million0.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$642,4160.01% of portfolio
-
Hohimer Wealth Management, LLC330KShares$633,6000.1% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$522,1860.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$278,8160.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$236,1600.61% of portfolio
-
Black Rock Inc. New York, NY84.6KShares$162,4700.0% of portfolio
-
Jones Financial Companies Lllp53.5KShares$102,7200.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny53.3KShares$102,2660.0% of portfolio
Latest Institutional Activity in GANX
Top Purchases
Top Sells
About GANX
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Insider Transactions at GANX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 09
2024
|
Khalid Islam Executive Chairman |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$50,000
$1.0 P/Share
|
|
Aug 09
2024
|
Gene Mack CFO and Interim CEO |
BUY
Open market or private purchase
|
Direct |
14,400
+50.0%
|
$14,400
$1.01 P/Share
|
|
Jul 01
2024
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
17,000
+2.87%
|
$17,000
$1.22 P/Share
|
|
Mar 28
2024
|
Jeffrey Scott Riley Director |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$90,000
$3.86 P/Share
|
|
Mar 26
2024
|
Matthias Alder Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,085
-22.35%
|
$24,340
$4.06 P/Share
|
|
Mar 26
2024
|
Matthias Alder Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,212
+15.81%
|
-
|
|
Dec 21
2023
|
Matthias Alder Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
206
-3.75%
|
$412
$2.46 P/Share
|
|
Dec 20
2023
|
Matthias Alder Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
637
+10.39%
|
-
|
|
Dec 07
2023
|
Matthias Alder Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,820
-27.27%
|
$3,640
$2.5 P/Share
|
|
Oct 01
2023
|
Matthias Alder Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
825
+11.0%
|
-
|
|
Sep 20
2023
|
Eric I Richman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
54,900
+16.76%
|
-
|
|
Sep 20
2023
|
Matthias Alder Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,550
+30.36%
|
-
|
|
Jul 01
2023
|
Matthias Alder Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,300
+50.0%
|
-
|
|
May 25
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
2,482
+1.13%
|
$4,964
$2.58 P/Share
|
|
May 20
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
9,256
+4.12%
|
$18,512
$2.83 P/Share
|
|
May 19
2022
|
Eric I Richman Director |
BUY
Open market or private purchase
|
Direct |
4,000
+1.9%
|
$8,000
$2.71 P/Share
|
|
May 19
2022
|
Salvatore Calabrese Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+27.03%
|
$24,300,000
$8100.0 P/Share
|
|
Aug 16
2021
|
Eric I Richman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,922
+2.22%
|
$34,454
$7.87 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 20.8K shares |
|---|---|
| Open market or private purchase | 111K shares |
| Payment of exercise price or tax liability | 6.09K shares |
|---|---|
| Open market or private sale | 2.03K shares |